EWSR1 and Ewing sarcoma: Erkizan utilized surface plasmon resonance screening to identify a lead compound that could block the binding of the transcription activator vital oncogene EWS-FLI1 to its functional partner RNA helicase A. This resulted in the induction of apoptosis in Ewing’s sarcoma cells and reduced the growth of Ewing’s sarcoma orthotopic xenografts.